Michael K. McGarrity
Chief Executive Officer at MDXHEALTH SA
Net worth: - $ as of 2024-04-29
Profile
Michael K.
McGarrity is currently the Chief Executive Officer & Executive Director at MDxHealth SA, the Chief Executive Officer & Director at MDxHealth, Inc., and the Chairman at LeviSense Medical, Inc. Previously, he served as the President, Chief Executive Officer & Director at Nanosphere, Inc. from 2013 to 2016, the Chief Executive Officer at Sterilis Solutions, LLC from 2017 to 2018, and the Vice President-Marketing at Stryker Corp.
from 1993 to 2005.
He obtained his undergraduate degree from the University of Notre Dame.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
MDXHEALTH S.A.
-.--% | 2023-03-30 | 0 ( -.--% ) | - $ | 2024-04-29 |
Michael K. McGarrity active positions
| Companies | Position | Start |
|---|---|---|
| MDXHEALTH SA | Chief Executive Officer | 2019-02-17 |
| LeviSense Medical, Inc. | Chairman | - |
MDxHealth, Inc.
 MDxHealth, Inc. BiotechnologyHealth Technology Part of MDxHealth SA, MDxHealth, Inc. is a precision diagnostics company that specializes in providing personalized molecular diagnostic information for the diagnosis and treatment of cancer. The company is based in Irvine, CA, with laboratory operations in Nijmegen and headquarters in Herstal, Belgium. The company's tests are based on proprietary genetic and epigenetic technologies that assist physicians in diagnosing urologic cancers and predicting recurrence risk. MDxHealth's ConfirmMDx for Prostate Cancer test helps to rule-in high-risk men who have had a previous negative biopsy result and rule-out otherwise cancer-free men from undergoing unnecessary repeat biopsies and screening procedures. | Chief Executive Officer | - |
Former positions of Michael K. McGarrity
| Companies | Position | End |
|---|---|---|
Sterilis Solutions, LLC
 Sterilis Solutions, LLC Medical SpecialtiesHealth Technology Sterilis LLC develops regulated medical waste remediation device. It sterilizes and grinds medical waste, rendering it acceptable for disposal in regular trash as described in OSHA and State regulations. The company was founded by Jeffrey H. Bell in June 2011 and is headquartered in Boxborough, MA. | Chief Executive Officer | 2017-12-31 |
| NANOSPHERE, INC. | Chief Executive Officer | 2016-08-31 |
| STRYKER CORPORATION | Sales & Marketing | 2004-12-31 |
Training of Michael K. McGarrity
| University of Notre Dame | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| STRYKER CORPORATION | Health Technology |
| MDXHEALTH SA | Health Technology |
| Private companies | 4 |
|---|---|
Nanosphere, Inc.
 Nanosphere, Inc. Medical SpecialtiesHealth Technology Nanosphere, Inc. engages in the development, manufacture, and market of molecular diagnostics platform. Its platform, Verigene System, enables clinicians to identify and treat bacteria and viruses responsible for some of the most complex, costly, and deadly infectious diseases. The company was founded by Chad A. Mirkin and Robert Letsinger on December 30, 1999 and is headquartered in Northbrook, IL. | Health Technology |
Sterilis Solutions, LLC
Sterilis Solutions, LLC Medical SpecialtiesHealth Technology Sterilis LLC develops regulated medical waste remediation device. It sterilizes and grinds medical waste, rendering it acceptable for disposal in regular trash as described in OSHA and State regulations. The company was founded by Jeffrey H. Bell in June 2011 and is headquartered in Boxborough, MA. | Health Technology |
| LeviSense Medical, Inc. | |
MDxHealth, Inc.
MDxHealth, Inc. BiotechnologyHealth Technology Part of MDxHealth SA, MDxHealth, Inc. is a precision diagnostics company that specializes in providing personalized molecular diagnostic information for the diagnosis and treatment of cancer. The company is based in Irvine, CA, with laboratory operations in Nijmegen and headquarters in Herstal, Belgium. The company's tests are based on proprietary genetic and epigenetic technologies that assist physicians in diagnosing urologic cancers and predicting recurrence risk. MDxHealth's ConfirmMDx for Prostate Cancer test helps to rule-in high-risk men who have had a previous negative biopsy result and rule-out otherwise cancer-free men from undergoing unnecessary repeat biopsies and screening procedures. | Health Technology |
- Stock Market
- Insiders
- Michael K. McGarrity
